(Q37964712)

26 August 2017

title

Entecavir: a review of its use in the treatment of chronic hepatitis B in patients with decompensated liver disease (English)

1 reference

26 August 2017

main subject

decompensated cirrhosis

1 reference

1 reference

1 reference

1 reference

1

Gillian M Keating

1 reference

26 August 2017

publication date

1 December 2011

1 reference

26 August 2017

1 reference

26 August 2017

volume

71

1 reference

26 August 2017

issue

18

1 reference

26 August 2017

page(s)

2511-2529

1 reference

The natural history of chronic HBV infection and geographical differences

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F11208510-000000000-00000

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208510-000000000-00000

National Institutes of Health consensus development conference statement: management of hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208510-000000000-00000

EASL Clinical Practice Guidelines: management of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208510-000000000-00000

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208510-000000000-00000

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208510-000000000-00000

Efficacy and safety of entecavir compared to lamivudine in nucleoside-naïve patients with chronic hepatitis B: a randomized double-blind trial in China

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208510-000000000-00000

Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208510-000000000-00000

A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208510-000000000-00000

Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208510-000000000-00000

Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208510-000000000-00000

Inhibition of hepatitis B virus polymerase by entecavir

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208510-000000000-00000

Delayed chain termination protects the anti-hepatitis B virus drug entecavir from excision by HIV-1 reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208510-000000000-00000

Entecavir for treatment of hepatitis B virus displays no in vitro mitochondrial toxicity or DNA polymerase gamma inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208510-000000000-00000

Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208510-000000000-00000

Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208510-000000000-00000

Viral dynamics during and after entecavir therapy in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208510-000000000-00000

The HBV drug entecavir - effects on HIV-1 replication and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208510-000000000-00000

Entecavir can select for M184V of HIV-1: a case of an HIV/hepatitis B (HBV) naïve patient treated for chronic HBV.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208510-000000000-00000

Entecavir therapy induces de novo HIV reverse-transcriptase M184V mutation in an antiretroviral therapy-naive patient

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208510-000000000-00000

Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208510-000000000-00000

Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208510-000000000-00000

Genotypic determinants and phenotypic properties of antiviral-resistant HBV variants: insight from entecavir resistance studies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208510-000000000-00000

Mechanistic characterization and molecular modeling of hepatitis B virus polymerase resistance to entecavir

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208510-000000000-00000

Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208510-000000000-00000

Use of the novel INNO-LiPA line probe assay for detection of hepatitis B virus variants that confer resistance to entecavir therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208510-000000000-00000

Dynamics of hepatitis B virus resistance to entecavir in a nucleoside/nucleotide-naïve patient

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208510-000000000-00000

Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: A randomized, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208510-000000000-00000

Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208510-000000000-00000

Mechanism of entecavir resistance of hepatitis B virus with viral breakthrough as determined by long-term clinical assessment and molecular docking simulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208510-000000000-00000

Lack of an effect of human immunodeficiency virus coinfection on the pharmacokinetics of entecavir in hepatitis B virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208510-000000000-00000

Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208510-000000000-00000

Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208510-000000000-00000

Treatment of chronic hepatitis B: Evolution over two decades.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208510-000000000-00000

A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208510-000000000-00000

Hepatitis B Virus Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208510-000000000-00000

Benefits and risks of nucleoside analog therapy for hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208510-000000000-00000

Side effects of long-term oral antiviral therapy for hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208510-000000000-00000

A comparison of 48-week treatment efficacy between clevudine and entecavir in treatment-naïve patients with chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208510-000000000-00000

Entecavir in decompensated HBV cirrhosis: the future is looking brighter

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208510-000000000-00000

Special populations with hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208510-000000000-00000

Entecavir for Treatment of Lamivudine-Refractory, HBeAg-Positive Chronic Hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208510-000000000-00000

Three Years of Continuous Entecavir Therapy in Treatment-Naïve Chronic Hepatitis B Patients: VIRAL Suppression, Viral Resistance and Clinical Safety

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208510-000000000-00000

Absence of a pharmacokinetic interaction between entecavir and adefovir

21 January 2018

1 reference

12 December 2020

Entecavir resistance is rare in nucleoside naïve patients with hepatitis B

1 reference

12 December 2020

Long-Term Treatment With Entecavir Induces Reversal of Advanced Fibrosis or Cirrhosis in Patients With Chronic Hepatitis B

1 reference

12 December 2020

Nucleoside analogues improve the short-term and long-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure

1 reference

12 December 2020

The natural history of chronic hepatitis B virus infection

1 reference

12 December 2020

Lactic acidosis during Entecavir treatment in decompensated hepatitis B virus-related cirrhosis

1 reference

12 December 2020

Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B

1 reference

12 December 2020

Pooled model-based approach to compare the pharmacokinetics of entecavir between Japanese and non-Japanese chronic hepatitis B patients

1 reference

12 December 2020

Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus

1 reference

12 December 2020

Entecavir pharmacokinetics, safety, and tolerability after multiple ascending doses in healthy subjects

1 reference

12 December 2020

10.2165/11208510-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

26 August 2017

1024806845

0 references

1 reference